SRBCF (Sirona Biochem) Scaled Net Operating Assets: -0.25 (As of Jul. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sirona Biochem Scaled Net Operating Assets?

Sirona Biochem SRBCF Scaled Net Operating Assets is -0.25 as of Jul. 2024.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sirona Biochem's operating assets for the quarter that ended in Jul. 2024 was $0.57 Mil. Sirona Biochem's operating liabilities for the quarter that ended in Jul. 2024 was $0.70 Mil. Sirona Biochem's Total Assets for the quarter that ended in Apr. 2024 was $0.53 Mil. Therefore, Sirona Biochem's scaled net operating assets (SNOA) for the quarter that ended in Jul. 2024 was -0.25.


Sirona Biochem Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Sirona Biochem's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sirona Biochem Scaled Net Operating Assets Chart

Sirona Biochem Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.06 -0.01 0.19 -0.70

Sirona Biochem Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 -0.78 -0.55 -0.51 -0.25

SRBCF vs MTNB, TCRT, QLGN: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Sirona Biochem's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sirona Biochem Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirona Biochem's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sirona Biochem's Scaled Net Operating Assets falls into.



Sirona Biochem Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sirona Biochem's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Oct. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Oct. 2023 )
=(Operating Assets (A: Oct. 2023 )-Operating Liabilities (A: Oct. 2023 ))/Total Assets (A: Oct. 2022 )
=(0.337-0.992)/0.943
=-0.69

where

Operating Assets(A: Oct. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.753 - 0.416
=0.337

Operating Liabilities(A: Oct. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.584 - 1.122 - 0.47
=0.992

Sirona Biochem's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jul. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jul. 2024 )
=(Operating Assets (Q: Jul. 2024 )-Operating Liabilities (Q: Jul. 2024 ))/Total Assets (Q: Apr. 2024 )
=(0.566-0.696)/0.527
=-0.25

where

Operating Assets(Q: Jul. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.59 - 0.024
=0.566

Operating Liabilities(Q: Jul. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3.116 - 1.296 - 1.124
=0.696

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.25 mean?
Sirona Biochem (SRBCF) has a Scaled Net Operating Assets of -0.25 as of Jul. 2024. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sirona Biochem and its competitors.
Is Sirona Biochem's Scaled Net Operating Assets too high?
Sirona Biochem's current Scaled Net Operating Assets is -0.25.
How does Sirona Biochem's Scaled Net Operating Assets compare to MTNB and TCRT?
Sirona Biochem's Scaled Net Operating Assets of -0.25 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sirona Biochem and its competitors. Sirona Biochem's current Scaled Net Operating Assets is -0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sirona Biochem stock overvalued right now?
Sirona Biochem (SRBCF) has a current Scaled Net Operating Assets of -0.25. The current Scaled Net Operating Assets is -0.25. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Sirona Biochem (SRBCF), the current Scaled Net Operating Assets is -0.25 as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sirona Biochem Business Description

Address C/o WeWork, 595 Burrard Street, Vancouver, BC, CAN, V7X 1L4
Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. The company has a business presence in Canada and France.